Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Hiroko MasudaKenichi HaranoSakiko MiuraYing WangYuko HirotaOi HaradaMohit Kumar JollyYuki MatsunagaBora LimAnita L WoodNapa ParinyanitikulHee Jin LeeGyungyub GongJason T GeorgeHerbert LevineJangsoon LeeXiaoping WangAnthony LucciArvind RaoBrock L SchweitzerO Rayne LawrenceRobert S SeitzStephan W MorrisDavid R HoutSeigo NakamuraSavitri KrishnamurthyNaoto T UenoPublished in: JCO precision oncology (2022)
We report, to our knowledge, for the first time that the TNBC molecular subtype and IM signature frequently change after NST. Our results also suggest that EMT is promoted by NST. Our findings may lead to innovative adjuvant therapy strategies in TNBC cases with residual tumor after NST.
Keyphrases
- locally advanced
- end stage renal disease
- ejection fraction
- rectal cancer
- newly diagnosed
- chronic kidney disease
- healthcare
- neoadjuvant chemotherapy
- epithelial mesenchymal transition
- peritoneal dialysis
- prognostic factors
- lymph node
- squamous cell carcinoma
- single molecule
- radiation therapy
- patient reported outcomes